CVB
Asset Logo

CurveBeam AI Limited

πŸ‡¦πŸ‡Ί ASX

🩺 HEALTH CARE

Compare
Add to watchlist
πŸ‘‘ Overview

πŸ“ˆ Performance

πŸ’΅ Cost

πŸ€“ Advanced

πŸ‘¨β€πŸ‘©β€πŸ‘§β€πŸ‘¦ Community

πŸ“ˆ

-63.97%
Annual Growth

1 years average annual growth

πŸ’΅

$ 500
Minimum Order

Due to regulatory requirements

🌏

5
Pearlers Invested

Since January 2020

πŸ‘‘ Overview

Key information
πŸ”Ž Fund Overview

CurveBeam AI Ltd. engages in the research, design, and manufacture of cone beam computed tomography imaging systems. The company is headquartered in Hatfield, Pennsylvania. The company went IPO on 2023-08-23. The firm is engaged in providing point-of-care diagnostic cone beam CT imaging solutions with artificial intelligence (AI) and deep learning AI (DLAI). Its product categories include orthopedics and bone health. Its orthopedics products include HiRise, LineUP, pedCAT Premium, pedCAT, InReach, and CubeVue Software. Its bone health products include InReach HR-pQCT, and OSSView. HiRise is a bilateral, weight bearing CT imaging of the entire lower extremities including hips/pelvis, distal upper extremities. LineUP is a bilateral, weight bearing CT imaging of the distal lower extremities and distal upper extremities. InReach HR-pQCT is a high resolution peripheral quantitative CT (HR-pQCT) imaging system designed for the point-of-care. OssView Bone Fragility software analyzes HR-pQCT images to measure the bone microarchitecture.

πŸ“ˆ Performance

Price History

-77.08%

1M

1Y

All Time

Graph

Table

Unsure how much or often to invest?
πŸ—“οΈ Investing frequency calculator

Determine the investment frequency needed to reach your goals

Try it out β†’
πŸ’΅ Investing amount calculator

Determine the recurring investment needed to reach your goals

Try it out β†’
⏱️ Investing duration calculator

Determine how long you will need to invest to reach your goals

Try it out β†’

πŸ’΅ Costs

πŸ’΅

6.50 AUD*
Purchase Fee

*$5.50 with Pearler Prepay

πŸ’Ό

N/A
Management Fee

Included in unit price, not charged by Pearler

πŸ’Έ

Want to know the long term costs?
Calculate the historic long term costs to hold your investments
πŸ’Έ Net fee calculator

πŸ€“ Advanced information

Technical Info

πŸ’° Price*

$0.11

*Price may be up to 24 hours old

πŸ‘©β€πŸ‘©β€πŸ‘¦ Community Insights

How our community is investing

🌏 Pearlers invested in CVB

5

πŸ“Š Total Capital Earnings

$7K

πŸ”ƒ Average investment frequency

31 weeks

πŸ’΅ Average investment amount

$3,005

⏰ Last time a customer invested in CVB

91 days
CVB investor breakdown
πŸ’΅ Income of investors

More than 200k

11%

150k - 200k

100k - 150k

11%

50k - 100k

33%

Less than 50k

33%
πŸ‘Ά Age of investors

18 - 25

26 - 34

20%

35 - 90

80%
πŸ™‹ Legal gender of investors

Female

60%

Male

40%

Pearlers who invest in CVB also invest in...

Vanguard MSCI Index International Shares ETF

VGS

VGS.AX was created on 2014-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard MSCI International Shares Index ETF seeks to track the return of the MSCI World ex-Australia Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax.

πŸ™Œ Performance (5Yr p.a)

12.86%

πŸ“Š Share price

$129.54 AUD

🌏 GLOBAL

⛳️ DIVERSIFIED

πŸ€– TECHNOLOGY

πŸ“ˆ HIGH PRICE GROWTH

Find Out More

IVV.AX was created on 2007-10-10 by iShares. The fund's investment portfolio concentrates primarily on large cap equity. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the performance of large capitalisation US equities.

πŸ™Œ Performance (5Yr p.a)

18.86%

πŸ“Š Share price

$57.74 AUD

πŸ“ˆ HIGH PRICE GROWTH

πŸ‡ΊπŸ‡Έ UNITED STATES

ASIA.AX was created on 2018-09-18 by BetaShares. The fund's investment portfolio concentrates primarily on information technology equity. The investment objective of the BetaShares Asia Technology Tigers ETF is to provide an investment return that aims to track the performance of the Solactive Asia ex-Japan Technology & Internet Tigers Index (the Index), before taking into account fees and expenses.

πŸ™Œ Performance (5Yr p.a)

9.64%

πŸ“Š Share price

$9.78 AUD

πŸ“ˆ HIGH PRICE GROWTH

πŸ‡¦πŸ‡Ί EX AUSTRALIA

A200.AX was created on 2018-05-07 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. The ETF currently has 6138.42m in AUM and 200 holdings. A200.AX aims to track the performance of an index (before fees and expenses) comprising 200 of the largest companies by market capitalisation listed on the ASX.

πŸ™Œ Performance (5Yr p.a)

4.30%

πŸ“Š Share price

$135.85 AUD

⛳️ DIVERSIFIED

πŸ’Έ FINANCIALS

NDQ.AX was created on 2015-05-26 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. The fund aims to track the performance of the NASDAQ-100 Index (before fees and expenses). The NASDAQ-100 comprises 100 of the largest non-financial companies listed on the NASDAQ market, and includes many companies that are at the forefront of the new economy.

πŸ™Œ Performance (5Yr p.a)

24.88%

πŸ“Š Share price

$45.04 AUD

πŸ€– TECHNOLOGY

πŸ“ˆ HIGH PRICE GROWTH

πŸ‡ΊπŸ‡Έ UNITED STATES

Want more shares? Try these...

CVC Ltd. engages in the provision of investment, development and venture capital, property finance and development, investment in listed entities, and funds management. The company is headquartered in Sydney, New South Wales. The firm's principal activities include property finance and development, the provision of investment and development capital and investment in other non-property opportunities. Its segments include property investment and non-property investment. The property investment segment includes investments in property related ordinary equity, preference equity, joint ventures, options to acquire an interest in direct property subject to planning outcomes and property backed lending. The non-property investment segment comprises listed investments, unlisted investments and secured lending opportunities that are non-property related. This segment also includes receivables, litigation claims and other investments. Its subsidiaries include Biggee Pty Limited, CVC Caboolture Unit Trust and Biomedical Systems Pty Limited.

πŸ™Œ Performance (5Yr p.a)

-2.88%

πŸ“Š Share price

$1.90 AUD

πŸ’Έ FINANCIALS

πŸ“Š Share price

$102.00 AUD

Copper Search Ltd. is a mineral exploration and development company focused on the Gawler Craton Region of South Australia. The firm is engaged in targeting the copper-gold deposits within the Gawler Craton of South Australia. Its projects include the Peake Project, Billa Kalina Project, and North Titan Project. Its Peake project is in the NE Gawler Craton, prospective for copper (IOCG) deposits. The company has 100% ownership of the 5,560 square kilometers (km2) of the Peake Project. The project is prospective for iron-ore-copper-gold (IOCG) and iron-sulphide-copper-gold (ISCG) deposits. The firm has identified six potential IOCG drill targets from over 40 geophysical anomalies. Its tenements are held through its 100%-owned subsidiary, Copper Search Australia Pty Ltd. Its tenements include Curdimurka, Anna Creek, Allandale, Mt Arthur, Stuarts Creek, Callana, Ruby Hill, Spring Hill, Mt Denison, Blyth Creek, Dismal Plain, and Wantaman. Its drilling aims to identify IOCG target deposits with similar scale potential to Prominent Hill and Carrapateena.

πŸ“Š Share price

$0.04 AUD

⛏️ MINING

Clinuvel Pharmaceuticals Ltd. operates as a biopharmaceutical company. The company is headquartered in Melbourne, Victoria. The company went IPO on 2001-02-13. The firm is focused on developing and commercializing treatments for patients with genetic, metabolic, systemic, and life-threatening, acute disorders, as well as healthcare solutions for specialized populations. Its lead therapy, SCENESSE (afamelanotide 16mg), is approved for commercial distribution in Europe, the USA, Israel, and Australia as the first systemic photoprotective drug for the prevention of phototoxicity (anaphylactoid reactions and burns) in adult patients with erythropoietic protoporphyria (EPP). The Company’s pharmaceuticals product development includes PRENUMBRA and NEURACTHEL. Its PhotoCosmetics product development includes CYACELLE and DNA Repair Assist and Melanogenesis. PRENUMBRA is a formulation of afamelanotide designed to provide a flexible dose in identified patient groups. NEURACTHEL is a novel formulation of the melanocortin adrenocorticotropic hormone (ACTH).

πŸ™Œ Performance (5Yr p.a)

-11.20%

πŸ“Š Share price

$13.70 AUD

🧬 BIOTECHNOLOGY

Compare
Add to watchlist